Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer

2021 ◽  
Author(s):  
Pierre Isnard ◽  
Julie Bruneau ◽  
Rebecca Sberro‐Soussan ◽  
Dominique Wendum ◽  
Christophe Legendre ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cellular Immune Responses ◽  
Cellular Immune

scholarly journals The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients

2018 ◽  
Vol 19 (12) ◽  
pp. 3945 ◽  
Author(s):  
Monika Lindemann ◽  
Johannes Korth ◽  
Ming Sun ◽  
Shilei Xu ◽  
Christoph Struve ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Estimated Glomerular Filtration Rate ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Flow Cytometric Data ◽  
Flow Cytometric ◽  
Allograft Function ◽  
Ifn Γ ◽  
Cellular Immune

In kidney transplant recipients, the cytomegalovirus (CMV) is frequently causing infection/reactivation and can trigger allograft rejection. To assess the risk of reactivation, the cellular immune response against CMV is increasingly assessed by cellular in vitro methods, such as the interferon (IFN)-γ ELISpot. In the current study we compared the IFN-γ ELISpot with our newly established CMV-specific ELISpot assays determining IL-17A, IL-21, IL-22, granzyme B, and perforin and correlated the results with flow cytometric data and clinical parameters. In 77 kidney transplant recipients, the highest frequency was observed for CMV pp65-specific cells secreting IFN-γ, followed by cells secreting IL-21 (62.9 and 23.2 Δ spot forming cells/105 cells). We observed a positive correlation between the percentage of CMV-specific CD3+ CD4+ CD154+ cells and results of the CMV-specific IL-21 ELISpot (p = 0.002). Results of the CMV pp65-specific IL-21 ELISpot correlated negatively with kidney function (estimated glomerular filtration rate, p = 0.006) and were significantly higher in women (p = 0.005). IL-21, a cytokine involved in aging that is secreted by activated CD4+ T cells, may also impact on allograft function. Thus, the CMV-specific IL-21 ELISpot could become a new tool to assess if CMV seropositivity represents a hazard for the graft.

scholarly journals Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients

2016 ◽  
Vol 17 (1) ◽  
pp. 281-286 ◽  
Author(s):  
D. Kumar ◽  
V. H. Ferreira ◽  
P. Campbell ◽  
K. Hoschler ◽  
A. Humar
Keyword(s):  
Immune Responses ◽  
Influenza Vaccine ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients

Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0003512021
Author(s):  
Thilo Kolb ◽  
Svenja Fischer ◽  
Lisa Müller ◽  
Nadine Lübke ◽  
Jonas Hillebrandt ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Kidney Failure ◽  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Dialysis Patients ◽  
Specific Antibodies ◽  
Neutralization Capacity

Background: Kidney failure patients on dialysis or after renal transplantation have a high risk for severe COVID-19 infection and vaccination against SARS-CoV-2 is the only expedient prophylaxis. Generally, immune responses are attenuated in kidney failure patients, however, systematic analyses of immune responses to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients (KTR) are still missing. Methods: In this prospective multicentric cohort study, antibody responses COVID-19 mRNA vaccines (BNT162b2; Biontech/Pfizer or mRNA-1273; Moderna) were measured in 32 dialysis patients and in 28 KTRs. SARS-CoV-2-specific antibodies and neutralization capacity were evaluated and compared to controls (n=78) in a similar age-range. Results: After the first vaccination, SARS-CoV-2-specific antibodies were nearly undetectable in kidney failure patients. After the second vaccination, 93% of the controls and 88% of dialysis patients but only 37% of KTRs developed SARS-CoV-2-specific IgG above cut-off. Moreover, mean IgG levels were significantly lower in KTRs (54±93 BAU/ml) compared to dialysis patients (503±481 BAU/ml, p<0.01). Both KTRs as well as dialysis patients had significantly lower IgG levels compared to controls (1992±2485 BAU/ml; p<0.001 and p<0.01). Importantly, compared to controls, neutralizing antibody titers were significantly lower in KTRs and dialysis patients. After the second vaccination, 76% of KTRs did not show any neutralization capacity against SARS-CoV-2 suggesting impaired seroprotection. Conclusions: Kidney failure patients show a significantly weaker antibody response compared to controls. Most strikingly, only one out four KTRs developed neutralizing antibodies against SARS-CoV-2 after two doses of vaccine. These data suggest that vaccination strategies need modification in immune transplant and dialysis patients.

scholarly journals 638. CMV-Specific T-Cell Immune Responses in Older vs. Younger Kidney Transplant Recipients

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S232-S232
Author(s):  
Emily Liang ◽  
Maura Rossetti ◽  
Gemalene Sunga ◽  
Elaine Reed ◽  
Joanna Schaenman
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Cell Immune Responses

scholarly journals Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients

Pathogens ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 67
Author(s):  
Simone Cosima Boedecker-Lips ◽  
Anja Lautem ◽  
Stefan Runkel ◽  
Pascal Klimpke ◽  
Daniel Kraus ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Cell Response ◽  
Cellular Response ◽  
Chronically Ill ◽  
Response Rates ◽  
Hemodialysis Patients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Antibody Titers

Hemodialysis patients (HDP) and kidney transplant recipients (KTR) have a high risk of infection with SARS-CoV-2 with poor clinical outcomes. Because of this, vaccination of these groups of patients against SARS-CoV-2 is particularly important. However, immune responses may be impaired in immunosuppressed and chronically ill patients. Here, our aim was to compare the efficacy of an mRNA-based vaccine in HDP, KTR, and healthy subjects. Design: In this prospective observational cohort study, the humoral and cellular response of prevalent 192 HDP, 50 KTR, and 28 healthy controls (HC) was assessed 1, 2, and 6 months after the first immunization with the BNT162b2 mRNA vaccine. Results: After 6 months, 97.5% of HDP, 37.9% of KTR, and 100% of HC had an antibody response. Median antibody levels were 1539.7 (±3355.8), 178.5 (±369.5), and 2657.8 (±2965.8) AU/mL in HDP, KTR, and HC, respectively (p ≤ 0.05). A SARS-CoV-2 antigen-specific cell response to vaccination was found in 68.8% of HDP, 64.5% of KTR, and 90% of HC. Conclusion: The humoral response rates to mRNA-based vaccination of HDPs are comparable to HCs, but antibody titers are lower. Furthermore, HDPs have weaker T-cell response to vaccination than HCs. KTRs have very low humoral and antigen-specific cellular response rates and antibody titers, which requires other vaccination strategies in addition to booster vaccination.

Sign in / Sign up

Export Citation Format

Share Document